First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006)

Background: Between April 2012 and July 2018, adult patients aged 25-65 years with newly diagnosed T-cell acute lymphoblastic leukaemia (T-ALL) in 48 UK centres were randomised at trial entry to receive standard of care (SOC) ALL induction phases I and II chemotherapy with or without the addition of single-agent nelarabine.